Friday closed down -0.95%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.99%, and the Nasdaq 100 Index ($IUXX) ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare sector as a whole. This time last year, the biotech ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $470.37, demonstrating a +1.88% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...

Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session.

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) on January 31 and set a price target of $515.00. The company’s shares closed last ...

US stocks fell sharply on Friday as investors digested a mixed January employment report amid an escalation of concerns about a trade war following comments from Donald Trump.

Our analysis of options history for Vertex Pharmaceuticals VRTX revealed 10 unusual trades. Delving into the details, we found 20% of traders were bullish, while 80% showed bearish tendencies.

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - February 10 ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges: variable efficacy vs opioids, generic competition, and entrenched prescriber habits limit near-term potential ...